Evidence map›Paper›PMID 35582354›Full record

ArticleJournal of clinical and experimental dentistry2022

Radiochemotheraphy-induced oral mucositis: Ectoin solution as a new treatment.

Adriana Fondevilla, Ana Serradilla, Elena Moreno-Olmedo, Kirill Matskov, María-José Belmonte, Antonio Sáez, María-José Acevedo, Escarlata López

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical and experimental dentistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Adriana FondevillaMD, PhD. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
Ana SerradillaMD. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
Elena Moreno-OlmedoMD. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
Kirill MatskovMD. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
María-José BelmonteNR. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
Antonio SáezNR. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
María-José AcevedoNR. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
Escarlata LópezMD, PhD. Department of Radiation Oncology. Vithas La Milagrosa Hospital, GenesisCare Madrid, Spain.
Hospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The current treatment for head and neck cancer involves radiotherapy, systemic therapy and surgery in a multidisciplinary approach. Unfortunately, cancer therapies can lead to local and systemic complications or side effects such as mucositis, which is the most common dose-dependent complication in the oral cavity and gastrointestinal tract. Mucositis can cause a considerably reduced quality of life in cancer patients already suffering from physical and psychological exhaustion. Moreover, radiotherapy interruptions due to toxicity can impact negatively in local control and survival. The main purpose of this study was to analyze patient satisfaction of Ectoin solution use in radiotherapy or radiochemotherapy-induced oral mucositis. Material and Methods: This is an institutional prospective analysis including 15 patients, conducted by two Spanish centers, between October 2019 and May 2020. Patients were treated with Ectoin solution during Radiotherapy and one month after the end of the treatment, three times per day. A seven-ítem Likert scale was used. We present our descriptive statistic regarding doctors and patients´s satisfaction. Results: Our results suggest that Ectoin solution relieves mucositis and is well tolerated by patients. Conclusions: We observed a favorable repercussion in the oral mucositis management and suggest a potential benefit of treating it.

Identifiers

PMID35582354
PMCPMC9094725
OpenAlexW4226322469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.